Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis.

Finnerty, James Patrick, Hussain, ABM Arad, Ponnuswamy, Aravind ORCID: 0000-0001-9901-969X, Kamil, Hafiz Gulzeb and Abdelaziz, Ammar (2023) Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis. BMC pulmonary medicine, 23 (1). p. 462.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1186/s12890-023-02761-5

Abstract

<h4>Background</h4>Factors predisposing to increased mortality with COVID-19 infection have been identified as male sex, hypertension, obesity, and increasing age. Early studies looking at airway diseases gave some contradictory results. The purpose of our study was to determine global variation in studies in patients hospitalized with COVID-19 in the prevalence of COPD and asthma; and to determine whether the presence of asthma or COPD affected mortality in the same hospital population.<h4>Methods</h4>A systematic review and meta-analysis of the published literature of COPD and asthma as co-morbidities in patients hospitalized with COVID-19 was performed, looking firstly at the prevalence of these diseases in patients hospitalized with COVID-19, and secondly at the relative risk of death from any cause for patients with asthma or COPD.<h4>Results</h4>Prevalence of both airway diseases varied markedly by region, making meaningful pooled global estimates of prevalence invalid and not of clinical utility. For individual studies, the interquartile range for asthma prevalence was 4.21 to 12.39%, and for COPD, 3.82 to 11.85%. The relative risk of death with COPD for patients hospitalized with COVID-19 was 1.863 (95% CI 1.640-2.115), while the risk with asthma was 0.918 (95% CI 0.767 to 1.098) with no evidence of increased mortality.<h4>Conclusions</h4>For asthma and COPD, prevalence in patients hospitalized with COVID-19 varies markedly by region. We found no evidence that asthma predisposed to increased mortality in COVID-19 disease. For COPD, there was clear evidence of an association with increased mortality.<h4>Trial registration</h4>The trial was registered with PROSPERO: registration number CRD42021289886.

Item Type:	Article
Uncontrolled Keywords:	Humans, Asthma, Pulmonary Disease, Chronic Obstructive, Prevalence, Comorbidity, Male, COVID-19
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences > School of Medicine
Depositing User:	Symplectic Admin
Date Deposited:	06 Feb 2024 09:38
Last Modified:	06 Feb 2024 09:38
DOI:	10.1186/s12890-023-02761-5
Open Access URL:	https://doi.org/10.1186/s12890-023-02761-5
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3178405